Theme by The WP Club . Proudly powered by WordPress
(Bloomberg Opinion) — Most of the public discussion about regaining our health and our wealth in the Covid-19 era is centered on the need for a vaccine. But vaccine development is expensive and highly uncertain. While we wait, people are dying and costs are piling up. More attention must be given to developing drugs to treat those who become ill.
Analysis I have done with colleagues Susan Athey (economics of technology professor, Stanford Graduate School of Business), Richard Frank (professor of health economics, Harvard Medical School) and Jonathan Gruber (Ford professor of economics, MIT) suggests the repurposing of generic drugs that have already been proved safe and effective in treating other diseases is an important part of the solution, and there is an urgent need for government support. More than 100 generic drug candidates have been identified as having promise to treat the symptoms of Covid-19. Some are already being
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.